The ASTIClite trial has recently commenced, coordinated by CTRU in conjunction with Barts Health NHS Trust as Sponsor, and led by Chief Investigator, Professor James Lindsay (Barts Health), and co-investigator Professor John Snowden (Sheffield Teaching Hospitals).

ASTIClite is a randomised controlled trial which aims to assess whether stem cell transplantation, with a low intensity treatment regimen, can reduce the symptoms and activity of Crohn's disease and enhance quality of life, compared to current standard care. The trial will also assess the safety of the procedure, explore the mechanisms involved in immune reconstitution and whether patients who do experience recurrent disease after the stem cell transplant will respond to treatments which had not worked previously. Participants are followed up over the course of a year, and are also invited to contribute longer term follow up data as part of an observational study through the European Society for Blood and Marrow Transplantation (EBMT).

ASTIClite is funded by the NIHR Efficacy and Mechanism Evaluation (EME) Programme (£2,333,194.12 funding award). The study has now received all the required regulatory approvals and site set up is in progress, with the aim of starting recruitment from April 2018.

For further information, please contact the ASTIClite Study Manager, Lizzie Swaby, at